Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Roots Analysis | PRODUCT CODE: 1250133

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1250133

Oral Solid Dosage Manufacturing Market - Distribution by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

PUBLISHED:
PAGES: 296 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

INTRODUCTION

Over the years, rising complexity of active pharmaceutical ingredients (APIs) has led to the development of a myriad of novel formulations that enable efficient drug delivery to the intended site of action. Nonetheless, th e demand for oral solid dosage (OSD) forms, including tablets and capsules, remains unparalleled. In fact, over two-thirds of the total drugs prescribed worldwide are dispensed in the form of oral solids. , In addition to being cost effective and relatively more stable as compared to their large molecule counterparts, these orally administered small molecules are patient-centric, and therefore play a critical role in fixing the medication adherence problem. Since the demand for oral solid drugs is rising, the development of modified oral solid formulations (including disintegrating tablets (ODTs), combination products and prolonged-, controlled-, and sustained- release dosage forms) that can improve API solubility and enhance bioavailability can offer the drug developers a huge opportunity to stand out in this mature and competitive market. However, the manufacturing of specialized solid doses, especially those containing highly potent APIs, from early development formulations to scale-up is a complex process that requires multidisciplinary expertise. Consequently, drug developers are increasingly relying on contract service providers with specialized equipment and a trained workforce to navigate the technical and routine operations-related challenges, including those associated with complex formulations, stringent regulatory requirements and multiple suppliers. Considering the immense popularity of oral solid dosage forms, especially amongst the pediatric and geriatric populations, we believe that the demand for conventional as well as modified oral solid formulations is likely to drive commendable growth within the contract manufacturing market in the coming years.

KEY MARKET INSIGHTS

The "Oral Solid Dosage Contract Manufacturing Market: Distribution by Type of Finished Dosage Form (Tablets, Capsules, Granules, Powders and Others), Type of Packaging (Blisters, Sachets, Inhalers, Bottles and Others), Scale of Operation (Preclinical, Clinical and Commercial), Company Size (Small, Mid-sized, Large and Very Large), Therapeutic Area (Oncological Disorder, Neurological Disorder, Cardiovascular Disorder, Infectious Disease, Metabolic Disorder, Respiratory Disorder, Immunological Disorder, Genetic Disorder, Gastrointestinal Disorder and Others, and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the oral solid dosage contract manufacturing, over a span of 12 years. The report answers the following key questions related to this domain.

Q1. What are the Current Opportunities within the Oral Solid Dosage Contract Manufacturing Market?

Although biologics have provided breakthroughs for the treatment of diseases with unmet medical needs, the approval of orally administered small molecule entities has been on the rise, recently. In fact, around 84% of the best-selling pharmaceuticals are administered orally. In addition, oral solids account for nearly 30% of the small molecules in the development pipeline. The oral solid dosage market is expected to continue to grow at a healthy rate, and as a result, we anticipate a surge in demand for the affiliated development and manufacturing support.

Q2. What is the Current Market Landscape and Recent Trends in the Oral Solid Drug Contract Manufacturing Domain?

Presently, close to 300 companies have the required capabilities to offer oral solid dosage contract manufacturing services across different scales of operation. More than 30% of these players serve as one-stop-shops, possessing an extensive range of capabilities (from formulation and analytical development to quality, regulatory support and commercialization) to meet client requirements. In order to cater to the increasing demand for OSD products, several CMOs and CDMOs have established strategic partnerships with other industry players and carried out expansion projects, thereby differentiating their offerings through niche enabling technologies, formulation expertise and manufacturing capacities, across different scales of operations.

Q3. What are the Key Benefits Offered by Oral Solid Dosage (OSD) Formulations?

Oral solid dosage formulations, including tablets, capsules, granules, sachets, powders, dry powder inhalers, and lozenges represent the most preferred dosage forms that are widely accepted by patients, worldwide. These time-tested means of treatment are relatively easy to manufacture, package and transport, offer good physical and chemical stability, and facilitate simple and accurate dosing. In addition, various coating methods make them easier to swallow, and allow modification of shape and color for aesthetic purposes. Moreover, the low production costs of oral solid formulations make them an economical option for manufacturers, healthcare institutions and patients.

Q4. What is the Need for Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) in the Oral Solid Dosage Domain?

Despite being the oldest and most-well understood formulation, oral solid dosage development and manufacturing is associated with several complications and challenges, including toxicity associated with potent APIs, complexity of formulations, deviations in quality, utility or transportation disruption and bottlenecks in process scale-up. Further, manufacturing of high-value dosage forms, including pediatric, geriatric, anti-abuse, controlled-release, and taste-masked drugs requires cutting-edge technologies which are expensive to acquire. As a result, around 60-70% of the companies engaged in this domain prefer to outsource their clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs), enabling the former to focus on their core research and development competencies.

Q5. What are the Key Challenges Faced by Oral Solid Dosage Contract Manufacturers?

The oral solid dosage contract manufacturing market is highly competitive, as several in-house pharmaceutical operations are being converted to offer CMO services and existing service providers are expanding their service offerings. Moreover, owing to the increase in consolidation within the pharmaceutical industry, the customer base for contract manufacturers is declining. In order to navigate the growing competition, oral solid dosage contract manufacturers are making an active effort to enhance their offerings by manufacturing high and uniform quality products in a cost-effective manner, while accommodating the diverse expectations of sponsor companies.

Q6. What are the Key Trends Shaping the Oral Solid Dosage Contract Manufacturing Industry?

Considering the evolving customer demands and continuous updates in the regulatory requirements, innovator companies and manufacturers of oral solid dosage products must upgrade their capabilities in order to maintain dominance in the overall pharmaceutical sector. From a regulatory perspective, concepts from Industry 4.0, including quality by design (QbD) and process analytical technology (PAT) principles, are increasingly being implemented to optimize and accelerate pharmaceutical processes. In addition, the paradigm shift from batch to continuous manufacturing is instrumental in lowering the investment and operating costs, while concurrently improving the product quality and reducing the time to market. The efforts to develop more agile, responsive, and reproducible manufacturing processes are being combined with the applications of advanced technologies, including track-and trace systems, nano-milling, 3D printing technology, which enable the production of highly engineered drug products in a streamlined manner.

Q7. What is the Market Size of the Oral Solid Dosage Contract Manufacturing Market?

The oral solid dosage form continues to play a major role in the contract manufacturing industry, representing about 60% of the market. In the foreseen future, as several promising leads move into the clinic and / or get commercialized, the oral solid dosage contract manufacturing market is projected to grow at a noteworthy rate, in the period between 2023-2035. The opportunities for growth within this industry primarily exist in the high potency products as well as the niche products, including fixed dose combinations, orally disintegrating tablets, minitablets, flavored chewables, double-layered and multiple-layers tablets. In terms of geography, the oral solid dosage contract manufacturing market in the Asia-Pacific region is anticipated to grow at a relatively faster pace by 2035.

Q8. Who are the Key Players in the Oral Solid Dosage Manufacturing Market?

Examples of key players engaged in this domain (which have also been captured in this report) include Aenova, Alcami, Almac, Cambrex, Catalent, CMIC, Contract Pharmacal, Delpharm, Hetero Drugs, Madras Pharmaceuticals, Micro Labs and Recipharm.

SCOPE OF THE REPORT

The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of oral solid dosage contract manufacturing market and its likely evolution in the mid-long term.
  • A general overview of oral solid dosage contract manufacturing, highlighting details on the various types and components of oral solid dosage forms. Additionally, it presents information on the oral solid dosage manufacturing process. Further, it highlights the emerging trends in oral solid dosage manufacturing domain, featuring information on the commonly outsourced manufacturing operations. The chapter concludes with a discussion on key considerations while selecting a CDMO partner, the affiliated risks and future perspectives of growth in this domain.
  • A detailed assessment of the overall market landscape of the companies offering oral solid dosage contract manufacturing services, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, company ownership (privately held and publicly owned), type of service provider (CDMOs and CMOs), type of business segment (active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs)) , type of service(s) offered (pre-formulation / formulation development, process development, analytical, scale-up, packaging, regulatory and others), type of finished dosage form(s) manufactured (tablet, capsules, granules, powders and others), type of packaging offered (blisters, sachets / pouches / bags, inhalers, bottles and others), scale(s) of operation (preclinical, clinical, and commercial) and additional manufacturing capabilities (continuous oral solid dosage manufacturing and highly potent oral solid dosage manufacturing. It also features information on the regulatory certifications and accreditations, along with information on the location of manufacturing facilities.
  • A detailed competitiveness analysis of oral solid dosage contract manufacturing service providers based on supplier strength (in terms of years of experience) and service strength (considering type of service(s) offered, type of finished dosage form(s), type of packaging offered, scale(s) of operation, regulatory certification(s) and location of facilities).
  • A detailed analysis of the capabilities of oral solid dosage contract manufacturers established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), based on several relevant parameters, including type of type of service(s) offered, type of finished dosage form(s) manufactured, type of packaging offered and scale(s) of operation.
  • Elaborate profiles of key players engaged in the contract manufacturing of oral solids (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, its financial information (if available), details on its oral solid dosage service portfolio, manufacturing capabilities and facilities, and recent developments and an informed future outlook.
  • An insightful make versus buy framework, highlighting the various factors that need to be taken into consideration by oral solid dosage drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO or CDMO partner.
  • A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective oral solid dosage contract manufacturing portfolios, based on a several relevant parameters, including year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of finished dosage form, geographical location of expanded facility, and most active players (in terms of number of expansions).
  • An estimate of the global installed capacity (in terms of number of oral solid units and volume of API) for the manufacturing of oral solids, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), type of finished dosage form (tablets, capsules, and others) and key geographical regions (North America, Europe, and Asia-Pacific and Rest of the World). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.
  • An informed estimate of the annual clinical and commercial demand for oral solids (in terms of volume of API), across key geographical regions and therapeutic areas.
  • A detailed analysis of the total cost of ownership for an oral solid dosage contract manufacturing service provider, highlighting the expenses associated with the establishment and maintenance of an oral solid dosage manufacturing facility, over a period of 20 years.
  • A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 300 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
  • A case study on the current market landscape of taste masking service providers for oral solids, providing information on scale of operation (preclinical / clinical and commercial), manufacturing scalability, other service(s) offered along with information on type of formulation (tablets, granules, capsules, semi-solids and others), end users (pharmaceutical, nutraceutical and others), techniques used for taste masking (hot melt extrusion, microencapsulation, coating, ion exchange resin and others), branch of healthcare (pediatrics, geriatrics and others) and regional capability. Further, the chapter includes the current market landscape of taste masking technology providers, providing information on technology name, techniques used, type of finished dosage form (tablets, capsules, powder and others), end users (pharmaceutical, nutraceutical and others) along with information on patent, availability of technology for partnerships and licensing. In addition, the chapter provides details on the year of establishment, company size and location of headquarters of companies providing taste masking services and technologies for oral solids.
  • A case study on the overall market landscape of bioavailability enhancement service providers for oral solids, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / micronization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, fine particles and semi-solids).

One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the oral solid dosage contract manufacturing market over the coming years. We have provided an informed estimate on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, including type of finished dosage form (tablets, capsules, granules, powders and others), type of packaging (blisters, sachets, inhalers, bottles and others), scale of operation (preclinical, clinical and commercial), company size (small, mid-sized, large and very large), therapeutic areas (oncological disorder, neurological disorder, cardiovascular disorder, infectious disease, metabolic disorder, respiratory disorder, immunological disorder, genetic disorder, gastrointestinal disorder and others), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via primary and secondary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary sources of information.

FREQUENTLY ASKED QUESTIONS

Question 1: What is the global market size of oral solid dosage contract manufacturing market?

Answer: The current oral solid contract manufacturing market size is anticipated to be over USD 30 billion.

Question 2: Which are the top players in the oral solid dosage contract manufacturing market?

Answer: Presently, close to 300 companies are engaged in offering oral solid dosage contract manufacturing market, worldwide. The top players engaged in this domain (which have also been captured in this report) include Aenova, Alcami, Almac, Cambrex, Catalent, CMIC, Contract Pharmacal, Delpharm, Hetero Drugs, Madras Pharmaceuticals, Micro Labs and Recipharm.

Question 3: How many contract service providers possess capabilities to handle oral solid therapies based on highly potent APIs (HPAPIs)?

Answer: Over 40% of the contract service providers engaged in this domain claim to have the requisite capabilities for the safe handling and containment of highly potent oral solids.

Question 4: What are the factors driving the oral solid dosage contract manufacturing market?

Answer: The factors driving the oral solid dosage contract manufacturing market include the emergence of virtual pharmaceutical companies, and the surge in demand for novel oral solid formulations, such as such as pediatric / geriatric, taste-masked, abuse-deterrent and control release products that improve patient compliance.

Question 5: Which region has the highest market share in the oral solid dosage contract manufacturing market?

Answer: North America captures around 60% share in the current oral solid dosage contract manufacturing market, followed by Europe.

Question 6: What are the leading market segments in the oral solid dosage contract manufacturing market?

Answer: Currently, the oral solid dosage contract manufacturing market is dominated by tablet and capsule formulations. This can be attributed to several advantages offered by these dosage forms, including portability, ease in swallowing, excellent bioavailability and medical adherence. Further, in terms of company size, established players (with over 10,000 employees) are likely to capture over 50% of the current and future market, owing to their enhanced capabilities and huge production capacities.

Question 7: What is the growth rate (CAGR) in the oral solid dosage contract manufacturing market?

Answer: The oral solid dosage contract manufacturing market size is projected to grow at a CAGR of ~6% in the coming years.

Question 8: What are the upcoming trends in the oral solid dosage contract manufacturing market?

Answer: The market is presently witnessing the adoption of Industry 4.0 concepts, such as QbD and PAT. Further, several service providers are establishing / expanding their continuous manufacturing lines for the production of oral solids, thereby reducing manufacturing cost (by 15-30%), manpower (by 50-70%) and power consumption (by 40%).

Question 9: What are the current initiatives undertaken by big pharma players engaged in the oral solid dosage contract manufacturing market?

Answer: In order to tap the lucrative opportunity in this rapidly growing market, big pharma players have undertaken several initiatives, including strengthening product portfolio, establishing agreements, acquisitions and making investments. For instance, in August 2022, Catalent acquired Metrics Contract Services for USD 475 million to expand its high-potent and oral solid dosage manufacturing capabilities.

CHAPTER OUTLINES

  • Chapter 1 is a preface providing an introduction to the full report, Oral Solid Dosage Contract Manufacturing Market, 2023-2035.
  • Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the oral solid dosage contract manufacturing market and its likely evolution in the short to mid-term and long term.
  • Chapter 3 provides a general overview of oral solid dosage contract manufacturing, highlighting details on the various types and components of oral solid dosage forms. Additionally, it presents information on oral solid dosage manufacturing process, featuring information on operations that are commonly outsourced to CDMOs and CMOs. The chapter concludes with a discussion on key considerations while selecting a CDMO partner, the affiliated risks and future perspectives of growth in this domain.
  • Chapter 4 includes detailed assessment of the overall market landscape of the companies offering oral solid dosage contract manufacturing services, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, company ownership (privately held and publicly owned), type of service provider (CDMOs and CMOs), type of business segment (active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs)), , type of service(s) offered (pre-formulation / formulation development, process development, analytical, scale-up, packaging, regulatory and others), type of finished form(s) manufactured (tablet, capsules, granules, powders and others), type of packaging offered (blisters, sachets / pouches / bags, inhalers, bottles and others) and scale(s) of operation (preclinical, clinical, and commercial) and additional manufacturing capabilities (continuous oral solid dosage manufacturing and highly potent oral solid dosage manufacturing). It also features information on the regulatory certifications and accreditations, along with information on the location of manufacturing facilities.
  • Chapter 5 presents a detailed competitiveness analysis of oral solid dosage contract manufacturing service providers based on supplier strength (in terms of years of experience) and service strength (considering type of service(s) offered, type of finished dosage form(s), type of packaging, scale(s) of operation, regulatory certification(s) and location of facilities).
  • Chapter 6 includes a detailed analysis of the capabilities of oral solid dosage contract manufacturers established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), based on several relevant parameters, including type of service(s) offered, type of finished dosage form(s), type of packaging offered and scale(s) of operation.
  • Chapter 7 features profiles of key players engaged in the contract manufacturing of oral solids (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, its financial information (if available) along with information on its oral solid dosage service portfolio, manufacturing capabilities and facilities, and recent developments and an informed future outlook.
  • Chapter 8 provides an insightful make versus buy framework, highlighting the various factors that need to be taken into consideration by oral solid dosage drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO or CDMO partner.
  • Chapter 9 presents a detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective oral solid dosage contract manufacturing portfolios, based on a several relevant parameters, including year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of finished dosage form manufactured, geographical location of expanded facility, and most active players (in terms of number of expansions).
  • Chapter 10 presents an estimate of the global, installed capacity (in terms of number of oral solid units and volume of API) for the manufacturing of oral solids, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), type of finished dosage form (tablets, capsules, others), and key geographical regions (North America, Europe, and Asia-Pacific and Rest of the World). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.
  • Chapter 11 includes an informed estimate of the annual clinical and commercial demand for oral solids (in terms of volume of API), across key geographical regions and therapeutic areas.
  • Chapter 12 provides a detailed analysis of the total cost of ownership for an oral solid dosage contract manufacturing service provider, highlighting the expenses associated with the establishment and maintenance of an oral solid dosage manufacturing facility, over a period of 20 years.
  • Chapter 13 features a detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 300 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
  • Chapter 14 features a case study on the current market landscape of taste masking service providers for oral solids, providing information on scale(s) of operation (preclinical / clinical and commercial), manufacturing scalability, other service(s) offered along with information on type of finished dosage form (tablets, granules, capsules, semi-solids and others), end users (pharmaceutical, nutraceutical and others), techniques used for taste masking (hot melt extrusion, microencapsulation, coating, ion exchange resin and others), branch of healthcare (pediatrics, geriatrics and others) and regional capability. Further, the chapter includes the current market landscape of taste masking technology providers, providing information on technology name, techniques used, type of finished dosage form (tablets, capsules, powder and others), end users (pharmaceutical, nutraceutical and others) along with information on patent, availability of technology for partnerships and licensing. In addition, the chapter provides details on the year of establishment, company size and location of headquarters of companies providing taste masking services and technologies for oral solids.
  • Chapter 15 features a case study on the overall market landscape of bioavailability enhancement service providers for oral solids, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / micronization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, fine particles and semi-solids).
Show more
Product Code: RA100424

TABLE OF CONTENTS

  • Chapter 16 presents a market forecast and opportunity analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on type of finished dosage form (tablets, capsules, granules, powders and others), type of packaging offered (blisters, sachets, inhalers, bottles and others), scale of operation (preclinical, clinical and commercial), company size (small, mid-sized, large and very large), therapeutic areas (oncological disorder, neurological disorder, cardiovascular disorder, infectious disease, metabolic disorder, respiratory disorder, immunological disorder, genetic disorder, gastrointestinal disorder and others), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).
  • Chapter 17 summarizes the overall report. It presents a list of key takeaways from the report and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.
  • Chapter 18 is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 19 is an appendix, which contains a list of companies and organizations mentioned in this report.
Show more
Product Code: RA100424

LIST OF TABLES

1. PREFACE

  • 1.1. Introduction
  • 1.2. Scope of the Report
  • 1.3. Market Segmentation
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Types of Dosage Forms
  • 3.3. Overview of Oral Solid Dosage Forms
    • 3.3.1. Components of Oral Solid Dosage Forms
    • 3.3.2. Classification of Oral Solid Dosage Forms
    • 3.3.3. Manufacturing of Oral Solid Dosage Forms
    • 3.3.4. Emerging Trends in Oral Solid Dosage Manufacturing
  • 3.4. Overview of Oral Solid Contract Manufacturing
    • 3.4.1. Services Offered by CMOs and CDMOs for Oral Solid Dosage
    • 3.4.2. Key Considerations while Selecting a CDMO Partner
    • 3.4.3. Risks and Challenges Associated with Outsourcing Oral Solid Dosage Manufacturing Operations
  • 3.5. Future Perspectives

4. ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS (CMOs): MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Oral Solid Dosage CMOs: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Manufacturing Facility
    • 4.2.5. Analysis by Company Ownership
    • 4.2.6. Analysis by Type of Service Provider
    • 4.2.7. Analysis by Type of Business Segment
    • 4.2.8. Analysis by Service(s) Offered
    • 4.2.9. Analysis by Company Size and Service(s) Offered
    • 4.2.10. Analysis by Location of Headquarters and Service(s) Offered
    • 4.2.11. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
    • 4.2.12. Analysis by Type of Oral Dosage Form Manufactured
    • 4.2.13. Analysis by Type of Packaging Offered
    • 4.2.14. Analysis by Scale of Operation
    • 4.2.15. Analysis by Additional Manufacturing Capabilities
      • 4.2.15.1. Availability of Continuous Oral Solid Dosage Manufacturing
      • 4.2.15.2. Availability of Highly Potent Oral Solid Dosage Manufacturing
    • 4.2.16. Analysis by Type of Business Segment and Scale of Operation
    • 4.2.17. Analysis by Service(s) Offered and Scale of Operation
    • 4.2.18. Analysis by Type of Packaging Offered and Scale of Operation
    • 4.2.19. Leading Players: Analysis by Number of Manufacturing Facilities

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions / Key Parameters
  • 5.3. Methodology
  • 5.4. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in North America
  • 5.5. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Europe
  • 5.6. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World
  • 5.7. Company Competitiveness Analysis: Benchmarking the Capabilities of Leading Players

6. REGIONAL CAPABILITY ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Key Assumptions and Methodology
  • 6.3. Oral Solid Dosage Contract Manufacturing Capabilities in North America
  • 6.4. Oral Solid Dosage Contract Manufacturing Capabilities in Europe
  • 6.5. Oral Solid Dosage Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
  • 6.6. Concluding Remarks

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Alcami
    • 7.2.1. Company Overview
    • 7.2.2. Service Portfolio
      • 7.2.2.1. Manufacturing Capabilities and Facilities
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. Cambrex
    • 7.3.1. Company Overview
    • 7.3.2. Service Portfolio
      • 7.3.2.1. Manufacturing Capabilities and Facilities
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. Catalent
    • 7.4.1. Company Overview
    • 7.4.2. Financial Information
    • 7.4.3. Service Portfolio
      • 7.4.3.1. Manufacturing Capabilities and Facilities
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. CMIC
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Service Portfolio
      • 7.5.3.1. Manufacturing Capabilities and Facilities
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. Contract Pharmacal
    • 7.6.1. Company Overview
    • 7.6.2. Financial Information
    • 7.6.3. Service Portfolio
      • 7.6.3.1. Manufacturing Capabilities and Facilities
    • 7.6.4. Recent Developments and Future Outlook
  • 7.7. Aenova
    • 7.7.1. Company Overview
    • 7.7.2. Financial Information
    • 7.7.3. Service Portfolio
      • 7.7.3.1. Manufacturing Capabilities and Facilities
    • 7.7.4. Recent Developments and Future Outlook
  • 7.8. Almac
    • 7.8.1. Company Overview
    • 7.8.2. Financial Information
    • 7.8.3. Service Portfolio
      • 7.8.3.1. Manufacturing Capabilities and Facilities
    • 7.8.4. Recent Developments and Future Outlook
  • 7.9. Delpharm
    • 7.9.1. Company Overview
    • 7.9.2. Service Portfolio
      • 7.9.2.1. Manufacturing Capabilities and Facilities
    • 7.9.3. Recent Developments and Future Outlook
  • 7.10. Hetero Drugs
    • 7.10.1. Company Overview
    • 7.10.2. Service Portfolio
      • 7.10.2.1. Manufacturing Capabilities and Facilities
    • 7.10.3. Recent Developments and Future Outlook
  • 7.11. Madras Pharmaceuticals
    • 7.11.1. Company Overview
    • 7.11.2. Service Portfolio
      • 7.11.2.1. Manufacturing Capabilities and Facilities
    • 7.11.3. Recent Developments and Future Outlook
  • 7.12. Micro Lab
    • 7.12.1. Company Overview
    • 7.12.2. Service Portfolio
      • 7.12.2.1. Manufacturing Capabilities and Facilities
    • 7.12.3. Recent Developments and Future Outlook
  • 7.13. Recipharm
    • 7.13.1. Company Overview
    • 7.13.2. Financial Information
    • 7.13.3. Service Portfolio
      • 7.13.3.1. Manufacturing Capabilities and Facilities
    • 7.13.4. Recent Developments and Future Outlook

8. MAKE VERSUS BUY DECISION FRAMEWORK

  • 8.1. Chapter Overview
  • 8.2. Assumptions and Key Parameters
  • 8.3. Oral Solid Dosage Contract Manufacturing: Make versus Buy Decision Making
    • 8.3.1. Scenario 1
    • 8.3.2. Scenario 2
    • 8.3.3. Scenario 3
    • 8.3.4. Scenario 4
  • 8.4. Concluding Remarks

9. RECENT EXPANSIONS

  • 9.1. Chapter Overview
  • 9.2. Oral Solid Dosage Contract Manufacturing: List of Expansions
    • 9.2.1. Analysis by Year of Expansion
    • 9.2.2. Analysis by Purpose of Expansion
    • 9.2.3. Analysis by Year and Purpose of Expansion
    • 9.2.4. Analysis by Type of Oral Solid Dosage Form Manufactured
    • 9.2.5. Analysis by Purpose of Expansion and Type of Oral Solid Dosage Form Manufactured
    • 9.2.6. Analysis by Location of Expanded Facility
    • 9.2.7. Analysis by Purpose of Expansion and Location of Expanded Facility
    • 9.2.8. Most Active Players: Analysis by Number of Recent Expansions

10. CAPACITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Key Assumptions and Methodology
    • 10.2.1 Oral Solid Dosage Manufacturing: Global Installed Capacity (by Number of Doses)
      • 10.2.1.1. Analysis by Company Size
      • 10.2.1.2. Analysis by Scale of Operation
      • 10.2.1.3. Analysis by Type of Formulation
      • 10.2.1.4. Analysis by Location of Manufacturing Facility
      • 10.2.1.5. Analysis by Company Size and Location of Manufacturing Facility
      • 10.2.1.6. Analysis by Scale of Operation and Location of Manufacturing Facility
      • 10.2.1.7. Analysis by Type of Formulation and Location of Manufacturing Facility
    • 10.2.2. Oral Solid Dosage Manufacturing: Global Installed Capacity (by Volume of Doses)
      • 10.2.2.1. Analysis by Company Size
      • 10.2.2.2. Analysis by Scale of Operation
      • 10.2.2.3. Analysis by Type of Formulation
      • 10.2.2.4. Analysis by Location of Manufacturing Facility
      • 10.2.2.5. Analysis by Company Size and Location of Manufacturing Facility
      • 10.2.2.6. Analysis by Scale of Operation and Location of Manufacturing Facility
      • 10.2.2.7. Analysis by Type of Formulation and Location of Manufacturing Facility
    • 10.2.3. Oral Solid Dosage Manufacturing: Global Installed Capacity (by Facility Area)
      • 10.2.3.1. Analysis by Company Size
      • 10.2.3.2. Analysis by Scale of Operation
      • 10.2.3.3. Analysis by Location of Manufacturing Facility
      • 10.2.3.4. Analysis by Company Size and Location of Manufacturing Facility
      • 10.2.3.5. Analysis by Scale of Operation and Location of Manufacturing Facility
  • 10.3. Concluding Remarks

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Overall Demand for Oral Solid Dosage Forms, 2023-2035
  • 11.4. Overall Commercial Demand for Oral Solid Dosage, 2023-2035
    • 11.4.1. Commercial Demand for Oral Solid Dosage: Analysis by Geography, 2023 and 2035
      • 11.4.1.1. Commercial Demand for Oral Solid Dosage in North America, 2023-2035
      • 11.4.1.2. Commercial Demand for Oral Solid Dosage in Europe, 2023-2035
      • 11.4.1.3. Commercial Demand for Oral Solid Dosage in Asia-Pacific and Rest of the World, 2023-2035
    • 11.4.2. Commercial Demand for Oral Solid Dosage: Distribution by Therapeutic Area, 2023 and 2035
      • 11.4.2.1. Commercial Demand for Oral Solid Dosage for Oncological Disorders, 2023-2035
      • 11.4.2.2. Commercial Demand for Oral Solid Dosage for Neurological Disorders, 2023-2035
      • 11.4.2.3. Commercial Demand for Oral Solid Dosage for Cardiovascular Disorders, 2023-2035
      • 11.4.2.4. Commercial Demand for Oral Solid Dosage for Infectious Diseases, 2023-2035
      • 11.4.2.5. Commercial Demand for Oral Solid Dosage for Metabolic Disorders, 2023-2035
      • 11.4.2.6. Commercial Demand for Oral Solid Dosage for Respiratory Disorders, 2023-2035
      • 11.4.2.7. Commercial Demand for Oral Solid Dosage for Immunological Disorders, 2023-2035
      • 11.4.2.8. Commercial Demand for Oral Solid Dosage for Genetic Disorders, 2023-2035
      • 11.4.2.9. Commercial Demand for Oral Solid Dosage for Gastrointestinal Disorders, 2023-2035
      • 11.4.2.10. Commercial Demand for Oral Solid Dosage for Other Disorders, 2023-2035
  • 11.5. Overall Clinical Demand for Oral Solid Dosage, 2023-2035
    • 11.5.1. Clinical Demand for Oral Solid Dosage: Analysis by Phase of Trial, 2023 and 2035
      • 11.5.1.1. Clinical Demand for Oral Solid Dosage in Phase I Trials, 2023-2035
      • 11.5.1.2. Clinical Demand for Oral Solid Dosage in Phase II Trials, 2023-2035
      • 11.5.1.3. Clinical Demand for Oral Solid Dosage in Phase III Trials, 2023-2035
  • 11.6. Demand and Supply Analysis

12. TOTAL COST OF OWNERSHIP FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS

  • 12.1. Chapter Overview
  • 12.2. Key Parameters
  • 12.3. Assumptions and Methodology
  • 12.4. Sample Dataset for the Estimation of Total Cost of Ownership
  • 12.5. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20
  • 12.6. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by CapEx and OpEx, Y0 and Y20
    • 12.6.1. Total Cost of Ownership for Oral Solid Contract Manufacturing Organizations: Analysis by CapEx, Y0
    • 12.6.2. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by OpEx, Y1-Y20
  • 12.7. Concluding Remarks

13. REGULATORY LANDSCAPE FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURERS

  • 13.1. Chapter Overview
  • 13.2. Regulatory Guidelines in North America
    • 13.2.1. The US Scenario
    • 13.2.2. Canadian Scenario
  • 13.3. Regulatory Guidelines in Europe
  • 13.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
    • 13.4.1. Chinese Scenario
    • 13.4.2. Indian Scenario
    • 13.4.3. Japanese Scenario
    • 13.4.4. South Korean Scenario
    • 13.4.5 Australian Scenario
    • 13.4.6. Brazilian Scenario
  • 13.5. Oral Solid Dosage CMOs: Information on Approvals from Various Regulatory Authorities
  • 13.6. Bubble Analysis: Regional Regulatory Summary

14. CASE STUDY ON TASTE MASKING SERVICES AND TECHNOLOGIES: MARKET LANDSCAPE

  • 14.1. Chapter Overview
  • 14.2. Taste Masking Service Providers
    • 14.2.1. Analysis by Year of Establishment
    • 14.2.2. Analysis by Company Size
    • 14.2.3. Analysis by Location of Headquarters
    • 14.2.4. Analysis by Year of Establishment and Location of Headquarters
    • 14.2.5. Analysis by Company Size and Location of Headquarters
  • 14.3. Taste Masking Services: Overall Market Landscape
    • 14.3.1. Analysis by Service(s) Offered
    • 14.3.2. Analysis by Scale of Operation
    • 14.3.3. Analysis by Other Service(s) Offered
    • 14.3.4. Analysis by Type of Formulation
    • 14.3.5. Analysis by End Users
    • 14.3.6. Analysis by Techniques Used for Taste Masking
    • 14.3.7. Analysis by Branch of Healthcare
    • 14.3.8. Analysis by Regional Capability
  • 14.4. Taste Masking Technologies: Overall Market Landscape
    • 14.4.1. Analysis by Service(s) Offered
    • 14.4.2. Analysis by Techniques Used
    • 14.4.3. Analysis by Type of Formulation
    • 14.4.4. Analysis by End Users
  • 14.5. Taste Masking Technology Providers
    • 14.5.1. Analysis by Year of Establishment
    • 14.5.2. Analysis by Company Size
    • 14.5.3. Analysis by Location of Headquarters
    • 14.5.4. Analysis by Year of Establishment and Location of Headquarters
    • 14.5.5. Analysis by Company Size and Location of Headquarters
    • 14.5.6. Leading Players: Analysis by Number of Technologies

15. CASE STUDY ON BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES: MARKET LANDSCAPE

  • 15.1. Chapter Overview
  • 15.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
    • 15.2.1. Analysis by Year of Establishment
    • 15.2.2. Analysis by Company Size
    • 15.2.3. Analysis by Location of Headquarters
    • 15.2.4. Analysis by Company Size and Location of Headquarters
    • 15.2.5. Leading Players: Analysis by Number of Technologies
  • 15.3. Bioavailability Enhancement Technologies: Market Landscape
    • 15.3.1. Analysis by Bioavailability Enhancement Principle
    • 15.3.2. Analysis by Bioavailability Enhancement Approach
    • 15.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
    • 15.3.4. Analysis by Type of Molecule
    • 15.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
    • 15.3.6. Analysis by Route of Administration
    • 15.3.7. Analysis by Availability for License
    • 15.3.8. Analysis by Intellectual Property Rights

16. MARKET FORECAST

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Forecast Methodology
  • 16.3. Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035
    • 16.3.1. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Finished Dosage Form
      • 16.3.1.1. Oral Solid Dosage Contract Manufacturing Market for Tablets, 2023-2035
      • 16.3.1.2. Oral Solid Dosage Contract Manufacturing Market for Capsules, 2023-2035
      • 16.3.1.3. Oral Solid Dosage Contract Manufacturing Market for Granules, 2023-2035
      • 16.3.1.4. Oral Solid Dosage Contract Manufacturing Market for Powders, 2023-2035
      • 16.3.1.5. Oral Solid Dosage Contract Manufacturing Market for Others, 2023-2035
    • 16.3.2. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Packaging
      • 16.3.2.1. Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035
      • 16.3.2.2. Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035
      • 16.3.2.3. Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035
      • 16.3.2.4. Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035
      • 16.3.2.5. Oral Solid Dosage Contract Manufacturing Market for Others, 2023-2035
    • 16.3.3. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Scale of Operation
      • 16.3.3.1. Oral Solid Dosage Contract Manufacturing Market for Preclinical Scale, 2023-2035
      • 16.3.3.2. Oral Solid Dosage Contract Manufacturing Market for Clinical Scale, 2023-2035
      • 16.3.3.3. Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035
    • 16.3.4. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Company Size
      • 16.3.4.1. Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035
      • 16.3.4.2. Oral Solid Dosage Contract Manufacturing Market for Mid-Sized Companies, 2023-2035
      • 16.3.4.3. Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035
      • 16.3.4.4. Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035
    • 16.3.5. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Therapeutic Area
      • 16.3.5.1. Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035
      • 16.3.5.2. Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035
      • 16.3.5.3. Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035
      • 16.3.5.4. Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035
      • 16.3.5.5. Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035
      • 16.3.5.6. Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035
      • 16.3.5.7. Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035
      • 16.3.5.8. Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035
      • 16.3.5.9. Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035
      • 16.3.5.10. Oral Solid Dosage Contract Manufacturing Market for Gastrointestinal Disorders, 2023-2035
      • 16.3.5.11. Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035
    • 16.3.6. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Geographical Regions
      • 16.3.6.1. Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035
      • 16.3.6.2. Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035
      • 16.3.6.3. Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035
      • 16.3.6.4. Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035
      • 16.3.6.5. Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035

17. CONCLUDING REMARKS

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

  • Table 3.1 Commonly Used Excipients in Tablet Formulation
  • Table 3.2 Contrasting Characteristics: Film-coated and Sugar-coated Tablets
  • Table 3.3 Contrasting Characteristics: Hard Gelatin and Soft Gelatin Capsules

Tablet 4.1 Oral Solid Dosage Contract Manufacturing: List of Companies

Tablet 4.2 Oral Solid Dosage Contract Manufacturers: Information on Service(s) Offered

Tablet 4.3 Oral Solid Dosage Contract Manufacturers: Information on Type of Oral Solid Dosage Form Manufactured

Tablet 4.4 Oral Solid Dosage Contract Manufacturers: Information on Type of Packaging Offered

Tablet 4.5 Oral Solid Dosage Contract Manufacturers: Information on Scale of Operation and Additional Manufacturing Capabilities

  • Table 6.1 Oral Solid Dosage Contract Manufacturers: Information on Manufacturing Facilities in North America
  • Table 6.2 Oral Solid Dosage Contract Manufacturers: Information on Manufacturing Facilities in Europe
  • Table 6.3 Oral Solid Dosage Contract Manufacturers: Information on Manufacturing Facilities in Asia-Pacific and Rest of the World
  • Table 7.1 Oral Solid Dosage Contract Manufacturing: List of Profiled Companies
  • Table 9.1 Oral Solid Dosage Contract Manufacturing: List of Expansions
  • Table 10.1 Global Installed Capacity for Oral Solid Dosage Contract Manufacturing: Average Capacity by Size of CMOs (Sample Data Set)
  • Table 10.2 Global Installed Capacity for Oral Solid Dosage Contract Manufacturing: Average Capacity by Size of CMOs
  • Table 11.1 Demand Analysis: Annual Demand for Oral Solid Dosage Forms, 2023-2035 (Metric Tons)
  • Table 11.2 Supply Analysis: Annual Demand for Oral Solid Dosage Forms, 2023-2035 (Metric Tons)
  • Table 13.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
  • Table 13.2 Oral Solid Dosage CMOs: Information on Approval from Various Regulatory Authorities
  • Table 13.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
  • Table 14.1 Taste Masking Service Providers: List of Companies
  • Table 14.2 Taste Masking Services: Information on Type of Service(s) Offered, Scale of Operation and Other Service(s) Offered
  • Table 14.3 Taste Masking Services: Information on Type of Formulation
  • Table 14.4 Taste Masking Services: Information on End Users, Techniques Used for TasteMasking, Branch of Healthcare and Regional Capability
  • Table 14.5 Taste Masking Technologies: Information on Type of Service(s) Offered and Techniques Used
  • Table 14.6 Taste Masking Technologies: Information on Type of Formulation
  • Table 14.7 Taste Masking Technologies: Information on End Users, Patent, Availability for Licensing and Partnerships
  • Table 14.8 List of Taste Masking Technology Providers
  • Table 15.1 List of Bioavailability Enhancement Service Providers
  • Table 15.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle
  • Table 15.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach
  • Table 15.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches
  • Table 15.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
  • Table 15.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches
  • Table 15.7 Bioavailability Enhancement Service Providers: Information on Other Bioavailability Enhancement Approaches
  • Table 15.8 Bioavailability Enhancement Service Providers: Information on Dosage Forms
  • Table 15.9 Bioavailability Enhancement Service Providers: Information on Routes of Administration
  • Table 15.10 List of Bioavailability Enhancement Technology Providers
  • Table 15.11 Bioavailability Enhancement Technologies: Information on Bioavailability Enhancement Principles and Bioavailability Enhancement Approaches
  • Table 15.12 Bioavailability Enhancement Technologies: Information on Type of Molecule
  • Table 15.13 Bioavailability Enhancement Technologies: Information on Dosage Forms
  • Table 15.14 Bioavailability Enhancement Technologies: Information on Routes of Administration
  • Table 15.15 Bioavailability Enhancement Technologies: Information on Availability for License and Intellectual Property Rights
  • Table 18.1 Oral Solid Dosage Contract Manufacturers: Analysis by Year of Establishment
  • Table 18.2 Oral Solid Dosage Contract Manufacturers: Analysis by Company Size
  • Table 18.3 Oral Solid Dosage Contract Manufacturers: Analysis by Location of Headquarters
  • Table 18.4. Oral Solid Dosage Contract Manufacturers: Analysis by Location of Manufacturing Facility
  • Table 18.5. Oral Solid Dosage Contract Manufacturers: Analysis by Company Ownership
  • Table 18.6. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Service Provider
  • Table 18.7. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Business Segment
  • Table 18.8. Oral Solid Dosage Contract Manufacturers: Analysis by Service(s) Offered
  • Table 18.9. Oral Solid Dosage Contract Manufacturers: Analysis by Company Size and Service(s) Offered
  • Table 18.10. Oral Solid Dosage Contract Manufacturers: Analysis by Location of Headquarters and Service(s) Offered
  • Table 18.11. Oral Solid Dosage Contract Manufacturers: Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
  • Table 18.12. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Oral Dosage Form Manufactured
  • Table 18.13. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Packaging Offered
  • Table 18.14. Oral Solid Dosage Contract Manufacturers: Analysis by Scale of Operation
  • Table 18.15. Oral Solid Dosage Contract Manufacturers: Availability of Continuous Oral Solid Dosage Manufacturing Capability
  • Table 18.16. Oral Solid Dosage Contract Manufacturers: Availability of Highly Potent Oral Solid Dosage Manufacturing Capability
  • Table 18.17. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Business Segment and Scale of Operation
  • Table 18.18. Oral Solid Dosage Contract Manufacturers: Analysis by Service(s) Offered and Scale of Operation
  • Table 18.19. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Packaging Offered and Scale of Operation
  • Table 18.20. Leading Oral Solid Contract Manufacturers: Distribution by Number of Manufacturing Facilities
  • Table 18.21 Regional Capability Analysis: Oral Solid Dosage Contract Manufacturers in North America
  • Table 18.22 Regional Capability Analysis: Oral Solid Dosage Contract Manufacturers in Europe
  • Table 18.23 Regional Capability Analysis: Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World
  • Table 18.24 Regional Capability Analysis: Comparison of Capabilities across Different Regions
  • Table 18.25 Catalent: Annual Revenues, FY 20118-2022 (USD Billion)
  • Table 18.26 CMIC: Annual Revenues, FY 2014-2020 (CNY Million)
  • Table 18.27 Aenova: Annual Revenues, FY 20118-2022 (EUR Thousand)
  • Table 18.28 Almac: Annual Revenues, FY 20118-2020 (EUR Million)
  • Table 18.29 Recipharm: Annual Revenues, FY 20118-2021 (EUR Million)
  • Table 18.30 Recent Expansions: Cumulative Year-Wise Trend, 2017-2022
  • Table 18.31 Recent Expansions: Distribution by Purpose of Expansion
  • Table 18.32 Recent Expansions: Distribution by Year and Purpose of Expansion
  • Table 18.33 Recent Expansions: Distribution by Type of Oral Dosage Form Manufactured
  • Table 18.34 Recent Expansions: Distribution by Purpose of Expansion and Type of Oral Solid Dosage Form Manufactured
  • Table 18.35 Recent Expansions: Distribution by Location of Expanded Facility
  • Table 18.36 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
  • Table 18.37 Most Active Players: Distribution by Number of Recent Expansions
  • Table 18.38 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Company Size
  • Table 18.39 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Scale of Operation
  • Table 18.40 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Type of Formulation
  • Table 18.41 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Location of Manufacturing Facility
  • Table 18.42 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Company Size and Location of Manufacturing Facility
  • Table 18.43 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Table 18.44 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Type of Formulation and Location of Manufacturing Facility
  • Table 18.45 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Company Size
  • Table 18.46 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Scale of Operation
  • Table 18.47 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Type of Formulation
  • Table 18.48 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Location of Manufacturing Facility
  • Table 18.49 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Company Size and Location of Manufacturing Facility
  • Table 18.50 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Table 18.51 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Type of Formulation and Location of Manufacturing Facility
  • Table 18.52 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Company Size
  • Table 18.53 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Scale of Operation
  • Table 18.54 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Location of Manufacturing Facility
  • Table 18.55 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Company Size and Location of Manufacturing Facility
  • Table 18.56 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Table 18.57 Global Demand for Oral Solid Dosage, 2023-2035 (Metric Ton)
  • Table 18.58 Global Commercial Demand for Oral Solid Dosage, 2023-2035 (Metric Ton)
  • Table 18.59 Commercial Demand for Oral Solid Dosage: Distribution by Geography, 2023-2035 (Metric Ton)
  • Table 18.60 Commercial Demand for Oral Solid Dosage in North America, 2023-2035 (Metric Ton)
  • Table 18.61 Commercial Demand for Oral Solid Dosage in Europe, 2023-2035 (Metric Ton)
  • Table 18.62 Commercial Demand for Oral Solid Dosage in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)
  • Table 18.63 Commercial Demand for Oral Solid Dosage: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)
  • Table 18.64 Commercial Demand for Oral Solid Dosage for Oncological Disorders, 2023-2035 (Metric Ton)
  • Table 18.65 Commercial Demand for Oral Solid Dosage for Neurological Disorders, 2023-2035 (Metric Ton)
  • Table 18.66 Commercial Demand for Oral Solid Dosage for Cardiovascular Disorders, 2023-2035 (Metric Ton)
  • Table 18.67 Commercial Demand for Oral Solid Dosage for Infectious Diseases, 2023-2035 (Metric Ton)
  • Table 18.68 Commercial Demand for Oral Solid Dosage for Metabolic Disorders, 2023-2035 (Metric Ton)
  • Table 18.69 Commercial Demand for Oral Solid Dosage for Respiratory Disorders, 2023-2035 (Metric Ton)
  • Table 18.70 Commercial Demand for Oral Solid Dosage for Immunological Disorders, 2023-2035 (Metric Ton)
  • Table 18.71 Commercial Demand for Oral Solid Dosage for Genetic Disorders, 2023-2035 (Metric Ton)
  • Table 18.72 Commercial Demand for Oral Solid Dosage for Gastrointestinal Disorders, 2023-2035 (Metric Ton)
  • Table 18.73 Commercial Demand for Oral Solid Dosage for Other Disorders, 2023-2035 (Metric Ton)
  • Table 18.74 Overall Clinical Demand for Oral Solid Dosage, 2023-2035 (Metric Ton)
  • Table 18.75 Clinical Demand for Oral Solid Dosage: Distribution by Phase of Trial, 2023 and 2035 (Metric Ton)
  • Table 18.76 Clinical Demand for Oral Solid Dosage in Phase I Trials, 2023-2035 (Metric Ton)
  • Table 18.77 Clinical Demand for Oral Solid Dosage in Phase II Trials, 2023-2035 (Metric Ton)
  • Table 18.78 Clinical Demand for Oral Solid Dosage in Phase III Trials, 2023-2035 (Metric Ton)
  • Table 18.79 Total Cost of Ownership: Types of Capital Expenditures (CapEx)
  • Table 18.80 Total Cost of Ownership: Types of Operational Expenditures (OpEx)
  • Table 18.81 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)
  • Table 18.82 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)
  • Table 18.83 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)
  • Table 18.84 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)
  • Table 18.85 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)
  • Table 18.86 Taste Masking Service Providers: Distribution by Year of Establishment
  • Table 18.87 Taste Masking Service Providers: Distribution by Company Size
  • Table 18.88 Taste Masking Service Providers: Distribution by Location of Headquarters
  • Table 18.89 Taste Masking Service Providers: Distribution by Year of Establishment and Location of Headquarters
  • Table 18.89 Taste Masking Service Providers: Distribution by Company Size and Location of Headquarters
  • Table 18.90 Taste Masking Services: Distribution by Service(s) Offered
  • Table 18.91 Taste Masking Services: Distribution by Scale of Operation
  • Table 18.92 Taste Masking Services: Distribution by Other Service(s) Offered
  • Table 18.93 Taste Masking Services: Distribution by Type of Formulation
  • Table 18.94 Taste Masking Services: Distribution by End Users
  • Table 18.95 Taste Masking Services: Distribution by Techniques Used for Taste Masking
  • Table 18.96 Taste Masking Services: Distribution by Branch of Healthcare
  • Table 18.97 Taste Masking Services: Distribution by Regional Capability
  • Table 18.98 Taste Masking Technologies: Distribution by Type of Service(s) Offered
  • Table 18.99 Taste Masking Technologies: Distribution by Techniques Used
  • Table 18.100 Taste Masking Technologies: Distribution by Type of Formulation
  • Table 18.101 Taste Masking Technologies: Distribution by End Users
  • Table 18.102 Taste Masking Technology Providers: Distribution by Year of Establishment
  • Table 18.103 Taste Masking Technology Providers: Distribution by Company Size
  • Table 18.104 Taste Masking Technology Providers: Distribution by Location of Headquarters
  • Table 18.105 Taste Masking Technology Providers: Distribution by Year of Establishment and Location of Headquarters
  • Table 18.106 Taste Masking Technology Providers: Distribution by Company Size and Location of Headquarters
  • Table 18.107 Popular Taste Masking Technology Providers: Distribution by Number of Technologies
  • Table 18.108 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
  • Table 18.109 Bioavailability Enhancement Service Providers: Distribution by Company Size
  • Table 18.110 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
  • Table 18.111 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 18.112 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
  • Table 18.113 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
  • Table 18.114 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
  • Table 18.115 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
  • Table 18.116 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
  • Table 18.117 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
  • Table 18.118 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
  • Table 18.119 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
  • Table 18.120 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
  • Table 18.121 Bioavailability Enhancement Technology Providers: Distribution by Company Size
  • Table 18.122 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 18.123 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 18.124 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
  • Table 18.125 Leading Players: Distribution by Number of Technologies
  • Table 18.126 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
  • Table 18.127 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
  • Table 18.128 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
  • Table 18.129 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
  • Table 18.130 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
  • Table 18.131 Bioavailability Enhancement Technologies: Distribution by Dosage Form
  • Table 18.132 Bioavailability Enhancement Technologies: Distribution by Route of Administration
  • Table 18.133 Bioavailability Enhancement Technologies: Distribution by Availability for License
  • Table 18.134 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
  • Table 18.135 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)
  • Table 18.136 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Finished Dosage Form
  • Table 18.137 Oral Solid Dosage Contract Manufacturing Market for Tablets, 2023-2035
  • Table 18.138 Oral Solid Dosage Contract Manufacturing Market for Capsules, 2023-2035
  • Table 18.139 Oral Solid Dosage Contract Manufacturing Market for Granules, 2023-2035
  • Table 18.140 Oral Solid Dosage Contract Manufacturing Market for Powders, 2023-2035
  • Table 18.141 Oral Solid Dosage Contract Manufacturing Market for Others, 2023-2035
  • Table 18.142 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Packaging
  • Table 18.143 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035
  • Table 18.144 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035
  • Table 18.145 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035
  • Table 18.146 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035
  • Table 18.147 Oral Solid Dosage Contract Manufacturing Market for Others, 2023-2035
  • Table 18.148 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Scale of Operation
  • Table 18.149 Oral Solid Dosage Contract Manufacturing Market for Preclinical Scale, 2023-2035
  • Table 18.150 Oral Solid Dosage Contract Manufacturing Market for Clinical Scale, 2023-2035
  • Table 18.151 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035
  • Table 18.152 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size (USD Billion)
  • Table 18.153 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023- 2035 (USD Billion)
  • Table 18.154 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023- 2035 (USD Billion)
  • Table 18.155 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023- 2035 (USD Billion)
  • Table 18.156 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023- 2035 (USD Billion)
  • Table 18.157 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Therapeutic Area
  • Table 18.158 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorder, 2023-2035
  • Table 18.159 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorder, 2023-2035
  • Table 18.160 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorder, 2023-2035
  • Table 18.161 Oral Solid Dosage Contract Manufacturing Market for Infectious Disease, 2023-2035
  • Table 18.162 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorder, 2023-2035
  • Table 18.163 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorder, 2023-2035
  • Table 18.164 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorder, 2023-2035
  • Table 18.165 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorder, 2023-2035
  • Table 18.166 Oral Solid Dosage Contract Manufacturing Market for Gastrointestinal Disorder, 2023-2035
  • Table 18.167 Oral Solid Dosage Contract Manufacturing Market for Other Disorder, 2023-2035
  • Table 18.168 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Geographical Regions
  • Table 18.169 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035
  • Table 18.170 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035
  • Table 18.171 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035
  • Table 18.172 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035
  • Table 18.173 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035
  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Landscape of Facilities
  • Figure 2.3 Executive Summary: Recent Expansions
  • Figure 2.4 Executive Summary: Capacity Analysis
  • Figure 2.5 Executive Summary: Demand Analysis
  • Figure 2.6 Executive Summary: Total Cost of Ownership
  • Figure 2.7 Executive Summary: Market Forecast
  • Figure 3.1 Properties of Dosage Forms
  • Figure 3.2 Types of Dosage Forms
  • Figure 3.3 Advantages and Disadvantages of Oral Solid Dosage Forms
  • Figure 3.4 Properties of Pharmaceutical Excipient
  • Figure 3.5 Type of Oral Solid Dosage Forms
  • Figure 3.6 Classification of Orally Administered Tablets
  • Figure 3.7 Tablet Processing Methods
  • Figure 3.8 Oral Solid Dosage Manufacturing Process
  • Figure 3.9 Services Offered by CDMOs and CMOs for Oral Solid Dosage
  • Figure 3.10 Key Considerations While Selecting a CDMO or CMO Partner
  • Figure 4.1 Oral Solid Dosage Contract Manufacturers: Analysis by Year of Establishment
  • Figure 4.2 Oral Solid Dosage Contract Manufacturers: Analysis by Company Size
  • Figure 4.3 Oral Solid Dosage Contract Manufacturers: Analysis by Location of Headquarters
  • Figure 4.4. Oral Solid Dosage Contract Manufacturers: Analysis by Location of Manufacturing Facility
  • Figure 4.5. Oral Solid Dosage Contract Manufacturers: Analysis by Company Ownership
  • Figure 4.6. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Service Provider
  • Figure 4.7. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Business Segment
  • Figure 4.8. Oral Solid Dosage Contract Manufacturers: Analysis by Service(s) Offered
  • Figure 4.9. Oral Solid Dosage Contract Manufacturers: Analysis by Company Size and Service(s) Offered
  • Figure 4.10. Oral Solid Dosage Contract Manufacturers: Analysis by Location of Headquarters and Service(s) Offered
  • Figure 4.11. Oral Solid Dosage Contract Manufacturers: Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
  • Figure 4.12. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Oral Dosage Form Manufactured
  • Figure 4.13. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Packaging Offered
  • Figure 4.14. Oral Solid Dosage Contract Manufacturers: Analysis by Scale of Operation
  • Figure 4.15. Oral Solid Dosage Contract Manufacturers: Availability of Continuous Oral Solid Dosage Manufacturing Capability
  • Figure 4.16. Oral Solid Dosage Contract Manufacturers: Availability of Highly Potent Oral Solid Dosage Manufacturing Capability
  • Figure 4.17. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Business Segment and Scale of Operation
  • Figure 4.18. Oral Solid Dosage Contract Manufacturers: Analysis by Service(s) Offered and Scale of Operation
  • Figure 4.19. Oral Solid Dosage Contract Manufacturers: Analysis by Type of Packaging Offered and Scale of Operation
  • Figure 4.20. Leading Oral Solid Contract Manufacturers: Distribution by Number of Manufacturing Facilities
  • Figure 5.1 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in North America
  • Figure 5.2 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in Europe
  • Figure 5.3 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World
  • Figure 5.4 Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top CMOs
  • Figure 6.1 Regional Capability Analysis: Oral Solid Dosage Contract Manufacturers in North America
  • Figure 6.2 Regional Capability Analysis: Oral Solid Dosage Contract Manufacturers in Europe
  • Figure 6.3 Regional Capability Analysis: Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World
  • Figure 6.4 Regional Capability Analysis: Comparison of Capabilities across Different Regions
  • Figure 7.1 Catalent: Annual Revenues, FY 2017-2022 (USD Billion)
  • Figure 7.2 CMIC: Annual Revenues, FY 2014-2020 (CNY Million)
  • Figure 7.3 Aenova: Annual Revenues, FY 2017-2022 (EUR Thousand)
  • Figure 7.4 Almac: Annual Revenues, FY 2017-2020 (EUR Million)
  • Figure 7.5 Recipharm: Annual Revenues, FY 2017-2021 (EUR Million)
  • Figure 8.1 Make versus Buy Decision Making Framework
  • Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 9.1 Recent Expansions: Cumulative Year-Wise Trend, 2017-2022
  • Figure 9.2 Recent Expansions: Distribution by Purpose of Expansion
  • Figure 9.3 Recent Expansions: Distribution by Year and Purpose of Expansion
  • Figure 9.4 Recent Expansions: Distribution by Type of Oral Dosage Form Manufactured
  • Figure 9.5 Recent Expansions: Distribution by Purpose of Expansion and Type of Oral Solid Dosage Form Manufactured
  • Figure 9.6 Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 9.7 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
  • Figure 9.8 Most Active Players: Distribution by Number of Recent Expansions
  • Figure 10.1 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Company Size
  • Figure 10.2 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Scale of Operation
  • Figure 10.3 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Type of Formulation
  • Figure 10.4 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Location of Manufacturing Facility
  • Figure 10.5 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Company Size and Location of Manufacturing Facility
  • Figure 10.6 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Figure 10.7 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Number of Doses): Distribution by Type of Formulation and Location of Manufacturing Facility
  • Figure 10.8 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Company Size
  • Figure 10.9 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Scale of Operation
  • Figure 10.10 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Type of Formulation
  • Figure 10.11 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Location of Manufacturing Facility
  • Figure 10.12 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Company Size and Location of Manufacturing Facility
  • Figure 10.13 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Figure 10.14 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Volume): Distribution by Type of Formulation and Location of Manufacturing Facility
  • Figure 10.15 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Company Size
  • Figure 10.16 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Scale of Operation
  • Figure 10.17 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Location of Manufacturing Facility
  • Figure 10.18 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Company Size and Location of Manufacturing Facility
  • Figure 10.19 Global Installed Oral Solid Dosage Contract Manufacturing Capacity (by Facility Area): Distribution by Scale of Operation and Location of Manufacturing Facility
  • Figure 11.1 Global Demand for Oral Solid Dosage, 2023-2035 (Metric Ton)
  • Figure 11.2 Commercial Demand for Oral Solid Dosage, 2023-2035 (Metric Ton)
  • Figure 11.3 Commercial Demand for Oral Solid Dosage: Distribution by Geography, 2023-2035 (Metric Ton)
  • Figure 11.4 Commercial Demand for Oral Solid Dosage in North America, 2023-2035 (Metric Ton)
  • Figure 11.5 Commercial Demand for Oral Solid Dosage in Europe, 2023-2035 (Metric Ton)
  • Figure 11.6 Commercial Demand for Oral Solid Dosage in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)
  • Figure 11.7 Commercial Demand for Oral Solid Dosage: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)
  • Figure 11.8 Commercial Demand for Oral Solid Dosage for Oncological Disorders, 2023-2035 (Metric Ton)
  • Figure 11.9 Commercial Demand for Oral Solid Dosage for Neurological Disorders, 2023-2035 (Metric Ton)
  • Figure 11.10 Commercial Demand for Oral Solid Dosage for Cardiovascular Disorders, 2023-2035 (Metric Ton)
  • Figure 11.11 Commercial Demand for Oral Solid Dosage for Infectious Diseases, 2023-2035 (Metric Ton)
  • Figure 11.12 Commercial Demand for Oral Solid Dosage for Metabolic Disorders, 2023-2035 (Metric Ton)
  • Figure 11.13 Commercial Demand for Oral Solid Dosage for Respiratory Disorders, 2023-2035 (Metric Ton)
  • Figure 11.14 Commercial Demand for Oral Solid Dosage for Immunological Disorders, 2023-2035 (Metric Ton)
  • Figure 11.15 Commercial Demand for Oral Solid Dosage for Genetic Disorders, 2023-2035 (Metric Ton)
  • Figure 11.16 Commercial Demand for Oral Solid Dosage for Gastrointestinal Disorders, 2023-2035 (Metric Ton)
  • Figure 11.17 Commercial Demand for Oral Solid Dosage for Other Disorders, 2023-2035 (Metric Ton)
  • Figure 11.18 Overall Clinical Demand for Oral Solid Dosage, 2023-2035 (Metric Ton)
  • Figure 11.19 Clinical Demand for Oral Solid Dosage: Distribution by Phase of Trial, 2023 and 2035 (Metric Ton)
  • Figure 11.20 Clinical Demand for Oral Solid Dosage in Phase I Trials, 2023-2035 (Metric Ton)
  • Figure 11.21 Clinical Demand for Oral Solid Dosage in Phase II Trials, 2023-2035 (Metric Ton)
  • Figure 11.22 Clinical Demand for Oral Solid Dosage in Phase III Trials, 2023-2035 (Metric Ton)
  • Figure 12.1 Total Cost of Ownership: Types of Capital Expenditures (CapEx)
  • Figure 12.2 Total Cost of Ownership: Types of Operational Expenditures (OpEx)
  • Figure 12.3 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)
  • Figure 12.4 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)
  • Figure 12.5 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)
  • Figure 12.6 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)
  • Figure 12.7 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)
  • Figure 13.1 Key Regulatory Requirements for CMOs and CROs in India
  • Figure 13.2 Regulatory Landscape for Oral Solid Dosage Contract Manufacturers: Distribution by Type of Regulatory Authorities
  • Figure 13.3 Bubble Analysis: Regional Regulatory Summary
  • Figure 14.1 Taste Masking Service Providers: Distribution by Year of Establishment
  • Figure 14.2 Taste Masking Service Providers: Distribution by Company Size
  • Figure 14.3 Taste Masking Service Providers: Distribution by Location of Headquarters
  • Figure 14.4 Taste Masking Service Providers: Distribution by Year of Establishment and Location of Headquarters
  • Figure 14.5 Taste Masking Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 14.6 Taste Masking Services: Distribution by Service(s) Offered
  • Figure 14.7 Taste Masking Services: Distribution by Scale of Operation
  • Figure 14.8 Taste Masking Services: Distribution by Other Service(s) Offered
  • Figure 14.9 Taste Masking Services: Distribution by Type of Formulation
  • Figure 14.10 Taste Masking Services: Distribution by End Users
  • Figure 14.11 Taste Masking Services: Distribution by Techniques Used for Taste Masking
  • Figure 14.12 Taste Masking Services: Distribution by Branch of Healthcare
  • Figure 14.13 Taste Masking Services: Distribution by Regional Capability
  • Figure 14.14 Taste Masking Technologies: Distribution by Type of Service(s) Offered
  • Figure 14.15 Taste Masking Technologies: Distribution by Techniques Used
  • Figure 14.16 Taste Masking Technologies: Distribution by Type of Formulation
  • Figure 14.17 Taste Masking Technologies: Distribution by End Users
  • Figure 14.18 Taste Masking Technology Providers: Distribution by Year of Establishment
  • Figure 14.19 Taste Masking Technology Providers: Distribution by Company Size
  • Figure 14.20 Taste Masking Technology Providers: Distribution by Location of Headquarters
  • Figure 14.21 Taste Masking Technology Providers: Distribution by Year of Establishment and Location of Headquarters
  • Figure 14.22 Taste Masking Technology Providers: Distribution by Company Size and Location of Headquarters
  • Figure 14.23 Popular Taste Masking Technology Providers: Distribution by Number of Technologies
  • Figure 15.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
  • Figure 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
  • Figure 15.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
  • Figure 15.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 15.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
  • Figure 15.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
  • Figure 15.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
  • Figure 15.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
  • Figure 15.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
  • Figure 15.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
  • Figure 15.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
  • Figure 15.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
  • Figure 15.13 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
  • Figure 15.14 Bioavailability Enhancement Technology Providers: Distribution by Company Size
  • Figure 15.15 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 15.16 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 15.17 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
  • Figure 15.18 Leading Players: Distribution by Number of Technologies
  • Figure 15.19 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
  • Figure 15.20 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
  • Figure 15.21 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
  • Figure 15.22 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
  • Figure 15.23 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
  • Figure 15.24 Bioavailability Enhancement Technologies: Distribution by Dosage Form
  • Figure 15.25 Bioavailability Enhancement Technologies: Distribution by Route of Administration
  • Figure 15.26 Bioavailability Enhancement Technologies: Distribution by Availability for License
  • Figure 15.27 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
  • Figure 16.1 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)
  • Figure 16.2 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Finished Dosage Form
  • Figure 16.3 Oral Solid Dosage Contract Manufacturing Market for Tablets, 2023-2035
  • Figure 16.4 Oral Solid Dosage Contract Manufacturing Market for Capsules, 2023-2035
  • Figure 16.5 Oral Solid Dosage Contract Manufacturing Market for Granules, 2023-2035
  • Figure 16.6 Oral Solid Dosage Contract Manufacturing Market for Powders, 2023-2035
  • Figure 16.7 Oral Solid Dosage Contract Manufacturing Market for Others, 2023-2035
  • Figure 16.8 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Packaging
  • Figure 16.9 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035
  • Figure 16.10 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035
  • Figure 16.11 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035
  • Figure 16.12 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035
  • Figure 16.13 Oral Solid Dosage Contract Manufacturing Market for Others, 2023-2035
  • Figure 16.14 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Scale of Operation
  • Figure 16.15 Oral Solid Dosage Contract Manufacturing Market for Preclinical Scale, 2023-2035
  • Figure 16.16 Oral Solid Dosage Contract Manufacturing Market for Clinical Scale, 2023-2035
  • Figure 16.17 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035
  • Figure 16.18 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size (USD Billion)
  • Figure 16.19 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023- 2035 (USD Billion)
  • Figure 16.20 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023- 2035 (USD Billion)
  • Figure 16.21 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023- 2035 (USD Billion)
  • Figure 16.22 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023- 2035 (USD Billion)
  • Figure 16.23 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Therapeutic Area
  • Figure 16.24 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorder, 2023-2035
  • Figure 16.25 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorder, 2023-2035
  • Figure 16.26 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorder, 2023-2035
  • Figure 16.27 Oral Solid Dosage Contract Manufacturing Market for Infectious Disease, 2023-2035
  • Figure 16.28 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorder, 2023-2035
  • Figure 16.29 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorder, 2023-2035
  • Figure 16.30 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorder, 2023-2035
  • Figure 16.31 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorder, 2023-2035
  • Figure 16.32 Oral Solid Dosage Contract Manufacturing Market for Gastrointestinal Disorder, 2023-2035
  • Figure 16.33 Oral Solid Dosage Contract Manufacturing Market for Other Disorder, 2023-2035
  • Figure 16.34 Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Geographical Regions
  • Figure 16.35 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035
  • Figure 16.36 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035
  • Figure 16.37 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035
  • Figure 16.38 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035
  • Figure 16.39 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035
  • Figure 17.1 Concluding Remarks: Overall Market Landscape
  • Figure 17.2 Concluding Remarks: Landscape of Manufacturing Facilities
  • Figure 17.3 Concluding Remarks: Recent Expansions
  • Figure 17.4 Concluding Remarks: Capacity Analysis
  • Figure 17.5 Concluding Remarks: Demand Analysis
  • Figure 17.6 Concluding Remarks: Total Cost of Ownership
  • Figure 17.7 Concluding Remarks: Market Forecast
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!